Search results
Results from the WOW.Com Content Network
The headers in the table listed below describe the following: Model – The marketing name for the GPU assigned by AMD/ATI.Note that ATI trademarks have been replaced by AMD trademarks starting with the Radeon HD 6000 series for desktop and AMD FirePro series for professional graphics.
The Radeon R100 is the first generation of Radeon graphics chips from ATI Technologies.The line features 3D acceleration based upon Direct3D 7.0 and OpenGL 1.3, and all but the entry-level versions offloading host geometry calculations to a hardware transform and lighting (T&L) engine, a major improvement in features and performance compared to the preceding Rage design.
Drug-induced autoimmune heamolytic anemia; Other names: Drug-induced immune hemolytic anemia, DIIHA. Blood smear from a patient with warm autoimmune hemolytic anemia showing spherocytes, marked polychromasia and a nucleated red blood cell. Specialty: Hematology: Symptoms: Fatigue, shortness of breath, dizziness, bloody urine, jaundice, weakness ...
ATI Radeon Xpress 1150 (ATI Radeon Xpress 200) May 23, 2006 Athlon 64, Athlon 64 FX, Athlon 64 X2, Sempron 110 1000 BI-DIRECTIONAL No Radeon X300 IGP, 400 MHz SB450, SB460, SB600, ULi M1575 A-Link Express II [a] RD480 ATI CrossFire Xpress 1600 (ATI Radeon Xpress 200 CrossFire Edition) September 27, 2005 Athlon 64, Athlon 64 FX, Athlon 64 X2 ...
The R300 GPU, introduced in August 2002 and developed by ATI Technologies, is its third generation of GPU used in Radeon graphics cards. This GPU features 3D acceleration based upon Direct3D 9.0 and OpenGL 2.0, a major improvement in features and performance compared to the preceding R200 design. R300 was the first fully Direct3D 9-capable ...
Previous GPU architectures implemented fixed-pipelines, i.e. there were distinct shader processors for each type of shader. TeraScale leverages many flexible shader processors which can be scheduled to process a variety of shader types, thereby significantly increasing GPU throughput (dependent on application instruction mix as noted below).
A 2013 study of over 400,000 people admitted to US hospitals found that 74% developed anemia at some point during their hospital stay. [5] Iatrogenic anemia is of particular concern in intensive care medicine, [6]: 629 because people who are critically ill require frequent blood tests and have a higher risk of developing anemia due to lower hemoglobin levels and impaired production of red ...
Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. [1] They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS.